• Recruiting

NCT04017130: Phase 1: Study to Evaluate the Safety, Tolerability, Pharmak & Efficacy of MT-0169 RRMM

Updated: May 26

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma


MT0169

This will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. MT-0169 is an investigational drug that recognizes and binds to the CD38 receptor, which may be found on the surface of multiple myeloma and non-Hodgkin lymphoma cancer cells. It delivers a dose of a modified toxin that kills these cells.


Sponsor

Molecular Templates, Inc


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT04017130


Official Title: A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma


First Posted : July 12, 2019


Click here for details on ClinicalTrials.gov


Click here for details on cancer.gov

 

Drug: MT-0169

Specifically Engineered to Eliminate CD38 Expressing Cells

 

Locations

United States, California

United States, Florida

United States, Indiana

United States, Minnesota

United States, Pennsylvania

United States, Tennessee



Posts Archive